Mar 30, 2014 by Dave WilliamsonNo April Fool's Joke: MannKind's Critical VoteMannKind's got a big vote coming up, and a key drug with a future in jeopardy.
Mar 30, 2014 by Dave Williamson and Michael DouglassMedicare Band-Aid Sends 1 Biotech Stock SurgingKeryx was the big winner in healthcare Thursday, up 17% in a single day due to both a successful drug and a success in Washington.
Mar 25, 2014 by Dave WilliamsonBest Buys for a Biotech BubbleThe biotech space may be in a bubble, and that bubble may be bursting. Here are one Fool analyst's picks on what he likes as a buy if a pullback in the space materializes.
Mar 24, 2014 by Dave WilliamsonHow Herbalife and Nu Skin Escaped Today's Health-Care Stock BloodbathAmidst a wash of suffering stocks in health care today, Herbalife and Nu Skin managed to shine.
Mar 23, 2014 by Dave Williamson and Michael DouglassWhen Avoiding U.S. Taxes Is a Smart PlayHorizon makes a strategic buy to move to Ireland away from U.S. taxes, and the market is thrilled.
Mar 23, 2014 by Dave Williamson and Michael DouglassWill Obamacare Hit Its Magic Number?Will the Affordable Care Act online exchanges enroll 6 million by the end of March.
Mar 23, 2014 by Dave Williamson and Michael DouglassControversial New Health Guidelines Have Doctors AlarmedNew cardiovascular recommendations would recommend a dramatic increase in statin use.
Mar 23, 2014 by Dave Williamson and Blake BosBetter Buy: General Electric vs. AbbVieWe've collected the most popular companies amongst Fool.com readers and put them head-to-head in a good old-fashioned challenge we're calling The Motley Fool's Better-Buy Tournament.
Mar 22, 2014 by Dave Williamson and Michael DouglassEndocyte, Inc. Still Has Huge Potential Post-90% PopThe biggest winner in biotech Friday was Endocyte, with its massive single-day 90% gain. Is there still time for investors to get in?
Mar 22, 2014 by Dave Williamson and Taylor MuckermanBetter Buy: Pfizer vs. CONSOL EnergyWe've collected the most popular companies amongst Fool.com readers and put them head-to-head in a good old-fashioned challenge we're calling The Motley Fool's Better Buy Tournament.
Mar 21, 2014 by Dave Williamson and Taylor MuckermanBetter Buy: Core Labs vs. AbbVieWe've collected the most popular companies amongst Fool.com readers and put them head-to-head in a good old-fashioned challenge we're calling The Motley Fool Better Buy Tournament.
Mar 19, 2014 by Dave Williamson and Jamal Carnette, CFABetter Buy: Twitter vs. Bristol-Myers SquibbWe've collected the most popular companies among Fool.com readers and put them head-to-head in a good old-fashioned challenge we're calling The Motley Fool Better Buy Tournament.
Mar 16, 2014 by Dave Williamson and Michael DouglassFirst Shots Fired in Insurance Market DisruptionHow the Affordable Care Act non-profit co-op loans are paying dividends and disrupting large insurers.
Mar 16, 2014 by Dave WilliamsonInvestors Don't Celebrate Celebrex Decision Favoring Cheap GenericsPfizer has a bad day in court and loses patent protection on a big blockbuster .
Mar 12, 2014 by Dave WilliamsonDo the Shorts Have the Upper Hand in Herbalife?Are the shorts starting to gain ground in the battle over Herbalife?
Mar 12, 2014 by Dave WilliamsonSuper Painkiller May Be in TroubleWith Zogenix's new super painkiller, the drug may work a little too well for its own good.
Mar 12, 2014 by Dave WilliamsonGeron Is Dead in the Water, but Not Sunk YetWhen people consider you an oncology company, losing your only oncology drug can sting.
Mar 10, 2014 by Dave Williamson3 Stocks Making Health-Care Investors Big Money TodayThe three biggest winners in health care today, and what drove the pops that are making investors big money.
Mar 9, 2014 by Dave WilliamsonWill Keeping Obama's Promise Break Obamacare?How HHS's changes to the Affordable Care Act affect managed-care stocks.
Mar 7, 2014 by Dave WilliamsonSurprise FDA Red Flags May Jeopardize Blockbuster DrugsCould Regeneron's drug be causing adverse effects to brain function in patients?
